DK2556091T3 - Antistof, som genkender human leukæmi-inhiberende faktor (LIF), og anvendelse af anti-LIF-antistoffer til behandling af sygdomme, der er forbundet med uønsket celleproliferation - Google Patents
Antistof, som genkender human leukæmi-inhiberende faktor (LIF), og anvendelse af anti-LIF-antistoffer til behandling af sygdomme, der er forbundet med uønsket celleproliferation Download PDFInfo
- Publication number
- DK2556091T3 DK2556091T3 DK11715676.0T DK11715676T DK2556091T3 DK 2556091 T3 DK2556091 T3 DK 2556091T3 DK 11715676 T DK11715676 T DK 11715676T DK 2556091 T3 DK2556091 T3 DK 2556091T3
- Authority
- DK
- Denmark
- Prior art keywords
- lif
- antibody
- fragment
- cancer
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5415—Leukaemia inhibitory factor [LIF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Radiology & Medical Imaging (AREA)
Claims (9)
1. Monoklonalt antistof eller et fragment deraf, som genkender human LIF med fuld længde, men ikke genkender et LIF-fragment svarende til aminosyrerne 1 til 160, hvor antistoffet produceres af hybridomcellelinjen DSM ACC3054, som er deponeret den 1. april 2010 af Vail d'Hebron Institute of Oncology hos Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH.
2. Hybridomcellelinjen DSM ACC3054, som er deponeret den 1. april 2010 afVall d'Hebron Institute of Oncology hos Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH.
3. Monoklonalt antistof eller et fragment deraf ifølge krav 1 eller et farmaceutisk præparat, som omfatter dette antistof eller et fragment deraf, til anvendelse til behandling af cancer.
4. Monoklonalt antistof eller et fragment deraf til anvendelse ifølge krav 3, hvor antistoffet eller fragmentet deraf virker ved inhibering af selv-regenerering af tumorstamceller.
5. Antistof eller et fragment deraf til anvendelse ifølge krav 3, hvor antistoffet eller fragmentet deraf er i stand til at reducere den cellepopulation, der er kendetegnet ved høje niveauer af CD 44 og Idl.
6. Farmaceutisk præparat, som omfatter en terapeutisk effektiv mængde af et antistof eller et fragment deraf ifølge krav 1 sammen med en farmaceutisk acceptabel bærer.
7. Immunanalytisk reagens, som anvendes til måling af human LIF, og som omfatter et monoklonalt antistof eller et fragment deraf ifølge krav 1.
8. Antistof eller et fragment deraf til anvendelse ifølge krav 3, hvor canceren er én af følgende: gliom, præ-B-celle akut lymfoblastisk leukæmi, akut myeloid leukæmi, lungecancer, colorektalt carcinom, blærecancer, duktal brystcancer, brystcarcinom, ovariecancer eller pankreascancer.
9. Monoklonalt antistof eller et fragment deraf til anvendelse ifølge krav 8, hvor gliomet er type IV gliom.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10380049A EP2371860A1 (en) | 2010-04-05 | 2010-04-05 | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
PCT/EP2011/055253 WO2011124566A1 (en) | 2010-04-05 | 2011-04-05 | Antibody recognizing human leukemia inhibitory factor (lif) and use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2556091T3 true DK2556091T3 (da) | 2017-01-16 |
Family
ID=42338260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11715676.0T DK2556091T3 (da) | 2010-04-05 | 2011-04-05 | Antistof, som genkender human leukæmi-inhiberende faktor (LIF), og anvendelse af anti-LIF-antistoffer til behandling af sygdomme, der er forbundet med uønsket celleproliferation |
Country Status (25)
Country | Link |
---|---|
US (3) | US8926956B2 (da) |
EP (3) | EP2371860A1 (da) |
JP (2) | JP6289906B2 (da) |
KR (5) | KR102294207B1 (da) |
CN (2) | CN103797031A (da) |
AU (1) | AU2011237922B2 (da) |
BR (1) | BR112012025517B1 (da) |
CA (1) | CA2797257A1 (da) |
CY (1) | CY1119451T1 (da) |
DK (1) | DK2556091T3 (da) |
EA (2) | EA202092276A3 (da) |
ES (1) | ES2608699T3 (da) |
HK (3) | HK1223384A1 (da) |
HR (1) | HRP20161736T1 (da) |
HU (1) | HUE030578T2 (da) |
IL (3) | IL222270A (da) |
LT (1) | LT2556091T (da) |
MX (2) | MX365054B (da) |
PL (1) | PL2556091T3 (da) |
PT (1) | PT2556091T (da) |
RS (1) | RS55539B1 (da) |
SG (1) | SG184429A1 (da) |
SI (1) | SI2556091T1 (da) |
SM (1) | SMT201600468T1 (da) |
WO (1) | WO2011124566A1 (da) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006271308B2 (en) * | 2005-07-19 | 2012-12-20 | Stemgen S.P.A. | Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS |
ES2363358B1 (es) * | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
EP2371860A1 (en) | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
EP3049110A2 (en) * | 2013-09-23 | 2016-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for targeting tumor microenvironment and for preventing metastasis |
TWI486172B (zh) * | 2013-11-08 | 2015-06-01 | Univ Chang Gung | 鼻咽癌治療的醫藥 |
AU2015314980A1 (en) * | 2014-09-10 | 2017-03-02 | The Regents Of The University Of California | Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies |
EP3273983B1 (en) | 2015-03-23 | 2021-05-05 | Evestra, Inc. | Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents |
EP3173483A1 (en) * | 2015-11-27 | 2017-05-31 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Agents for the treatment of diseases associated with undesired cell proliferation |
WO2018115960A1 (en) * | 2016-12-19 | 2018-06-28 | Mosaic Biomedicals, S.L. | Antibodies against lif and uses thereof |
MX2019007376A (es) * | 2016-12-19 | 2020-02-07 | Mosaic Biomedicals S L U | Anticuerpos contra el lif y usos de los mismos. |
WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
AU2019251289B2 (en) | 2018-04-12 | 2024-01-18 | Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats | Combination of LIF inhibitors and PD-1 axis inhibitors for use in treating cancer |
SG11202011170YA (en) * | 2018-05-14 | 2020-12-30 | Medimmune Ltd | Antibodies against lif and dosage forms thereof |
MA52300A (fr) * | 2018-06-18 | 2021-04-21 | Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron | Combinaison d'inhibiteurs de lif et d'agents anti-néoplasiques à base de platine à utiliser dans le traitement du cancer |
CN112703202A (zh) * | 2018-06-18 | 2021-04-23 | 免疫医疗有限公司 | 用于改善患有癌症的个体对抗lif抗体治疗的反应的方法 |
WO2021057991A1 (zh) * | 2019-09-29 | 2021-04-01 | 北京加科思新药研发有限公司 | 对lif具有特异性的结合分子及其用途 |
CN111020030A (zh) * | 2019-12-03 | 2020-04-17 | 中山大学 | 一种骨肉瘤干细胞标志物及其应用、试剂盒 |
CN111378036B (zh) * | 2020-01-09 | 2021-08-10 | 北京浩古元方生物医药科技有限公司 | 一种抗人白血病抑制因子单克隆抗体的制备方法及其应用 |
CN112294812B (zh) * | 2020-11-18 | 2022-08-16 | 新乡医学院 | 一种小分子抑制剂在制备抗肿瘤药物方面的应用 |
CN114672460B (zh) * | 2021-12-21 | 2023-06-23 | 中国人民解放军军事科学院军事医学研究院 | 一种靶向cd44的异质型cic细胞模型的制备方法及应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
GB9004890D0 (en) | 1990-03-05 | 1990-05-02 | Heath John K | Leukaemia inhibitory factor |
ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
JPH05304986A (ja) | 1992-04-28 | 1993-11-19 | Tosoh Corp | gp130蛋白質に対するモノクロ−ナル抗体 |
WO1993023556A1 (en) | 1992-05-08 | 1993-11-25 | Genentech, Inc. | Antibodies to leukemia inhibitory factor |
WO1993023665A1 (en) | 1992-05-15 | 1993-11-25 | Re/Map Incorporated | Electromagnetic shielding for a liquid conditioning device |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
AU702375B2 (en) * | 1995-04-24 | 1999-02-18 | Genentech Inc. | Use of leukemia inhibitory factor and endothelin antagonists |
US20050147609A1 (en) | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
PL220113B1 (pl) | 1999-01-15 | 2015-08-31 | Genentech Inc | Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
EP1497445A2 (en) | 2002-04-01 | 2005-01-19 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
EP1576131A4 (en) * | 2002-08-15 | 2008-08-13 | Genzyme Corp | EXPRESSION PATTERN IN BRAIN DENTHELIC CELLS |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2005030803A1 (en) | 2003-09-29 | 2005-04-07 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic molecules |
CN101052717A (zh) | 2004-05-11 | 2007-10-10 | α基因株式会社 | 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法 |
EP1612558A1 (en) | 2004-06-30 | 2006-01-04 | Academisch Ziekenhuis Leiden | Method for detecting gluten |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
US20110135645A1 (en) | 2006-10-04 | 2011-06-09 | The Scripps Research Institute | Human antibodies neutralizing human metapneumovirus |
CN101440128A (zh) * | 2007-11-21 | 2009-05-27 | 中国人民解放军第二军医大学 | 人脑胶质瘤中差异表达的蛋白及其用途 |
WO2010054499A1 (en) * | 2008-11-11 | 2010-05-20 | Telefonaktiebolaget L M Ericsson (Publ) | A dpd system with multiple transmitter paths |
ES2363358B1 (es) | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
WO2011057144A2 (en) | 2009-11-06 | 2011-05-12 | La Jolla Institute For Allergy And Immunology | Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses |
CN102167742B (zh) | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗her2单克隆抗体、其制备方法及用途 |
EP2371860A1 (en) | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
TWI486172B (zh) | 2013-11-08 | 2015-06-01 | Univ Chang Gung | 鼻咽癌治療的醫藥 |
-
2010
- 2010-04-05 EP EP10380049A patent/EP2371860A1/en not_active Withdrawn
-
2011
- 2011-04-05 KR KR1020207028482A patent/KR102294207B1/ko active IP Right Grant
- 2011-04-05 HU HUE11715676A patent/HUE030578T2/en unknown
- 2011-04-05 EA EA202092276A patent/EA202092276A3/ru unknown
- 2011-04-05 MX MX2015008974A patent/MX365054B/es unknown
- 2011-04-05 CN CN201180027552.6A patent/CN103797031A/zh active Pending
- 2011-04-05 ES ES11715676.0T patent/ES2608699T3/es active Active
- 2011-04-05 KR KR1020127028860A patent/KR20130121679A/ko not_active Application Discontinuation
- 2011-04-05 WO PCT/EP2011/055253 patent/WO2011124566A1/en active Application Filing
- 2011-04-05 SG SG2012073557A patent/SG184429A1/en unknown
- 2011-04-05 CA CA2797257A patent/CA2797257A1/en not_active Abandoned
- 2011-04-05 DK DK11715676.0T patent/DK2556091T3/da active
- 2011-04-05 EP EP16154907.6A patent/EP3045473A1/en not_active Withdrawn
- 2011-04-05 JP JP2013503084A patent/JP6289906B2/ja active Active
- 2011-04-05 SI SI201131028A patent/SI2556091T1/sl unknown
- 2011-04-05 BR BR112012025517-7A patent/BR112012025517B1/pt not_active IP Right Cessation
- 2011-04-05 US US13/261,464 patent/US8926956B2/en active Active
- 2011-04-05 KR KR1020177031786A patent/KR20170125137A/ko not_active Application Discontinuation
- 2011-04-05 LT LTEP11715676.0T patent/LT2556091T/lt unknown
- 2011-04-05 AU AU2011237922A patent/AU2011237922B2/en not_active Ceased
- 2011-04-05 PL PL11715676T patent/PL2556091T3/pl unknown
- 2011-04-05 KR KR1020187018882A patent/KR20180078352A/ko active Application Filing
- 2011-04-05 RS RS20161123A patent/RS55539B1/sr unknown
- 2011-04-05 CN CN201810679717.1A patent/CN109320609A/zh active Pending
- 2011-04-05 EA EA201201373A patent/EA036698B9/ru not_active IP Right Cessation
- 2011-04-05 KR KR1020197015171A patent/KR20190061098A/ko not_active Application Discontinuation
- 2011-04-05 MX MX2012011636A patent/MX2012011636A/es active IP Right Grant
- 2011-04-05 PT PT117156760T patent/PT2556091T/pt unknown
- 2011-04-05 EP EP11715676.0A patent/EP2556091B1/en active Active
-
2012
- 2012-10-09 IL IL222270A patent/IL222270A/en active IP Right Grant
-
2013
- 2013-07-10 HK HK16111721.5A patent/HK1223384A1/zh unknown
- 2013-07-10 HK HK13108092.5A patent/HK1180702A1/zh not_active IP Right Cessation
-
2014
- 2014-11-04 HK HK14111011.6A patent/HK1208469A1/xx unknown
-
2015
- 2015-01-05 US US14/589,033 patent/US20150139989A1/en not_active Abandoned
- 2015-10-07 IL IL241952A patent/IL241952A/en active IP Right Grant
-
2016
- 2016-07-01 JP JP2016131179A patent/JP6483059B2/ja active Active
- 2016-12-16 HR HRP20161736TT patent/HRP20161736T1/hr unknown
- 2016-12-22 SM SM201600468T patent/SMT201600468T1/it unknown
- 2016-12-22 CY CY20161101328T patent/CY1119451T1/el unknown
-
2017
- 2017-09-25 IL IL254664A patent/IL254664B/en unknown
-
2018
- 2018-05-14 US US15/978,362 patent/US10968273B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10968273B2 (en) | Antibody recognizing human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation | |
CN111213059B (zh) | 用于癌症的诊断和治疗方法 | |
BR112019014694A2 (pt) | anticorpos anti-cd47 e usos dos mesmos | |
CN104662044A (zh) | 用于治疗ror1癌症并抑制转移的抗体和疫苗 | |
JP2010535713A (ja) | 抗tweak受容体抗体の治療上の使用 | |
WO2020168555A1 (zh) | Cd3抗原结合片段及其应用 | |
AU2016359920A1 (en) | Agents for the treatment of diseases associated with undesired cell proliferation | |
US20220127374A1 (en) | ANTIBODIES AGAINST hEPCR | |
KR20210079311A (ko) | 육종성 신장암에 대한 진단과 치료 방법 | |
JP2015514062A (ja) | E−カドヘリンの細胞外ドメインの阻害剤を含む併用療法 | |
JP2024028867A (ja) | Pd-1軸結合拮抗薬、白金剤、およびトポイソメラーゼii阻害剤で肺癌を治療する方法 | |
WO2005084708A1 (ja) | Cxcr3阻害剤を含有する医薬組成物 | |
US20230192833A1 (en) | New anti-VEGFC antibodies and uses thereof | |
KR20210062634A (ko) | 3중-음성 유방암에 대한 진단 방법 | |
CN109476759B (zh) | Prl3抗体 | |
WO2018084236A1 (ja) | プロレニン受容体に対する抗体またはその抗原結合断片、およびその用途 | |
JP2015196666A (ja) | 中和活性を有する抗lr11モノクローナル抗体、及びそれを含有してなる医薬 |